539 related articles for article (PubMed ID: 11773173)
41. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation.
Bierman PJ; Lynch JC; Bociek RG; Whalen VL; Kessinger A; Vose JM; Armitage JO
Ann Oncol; 2002 Sep; 13(9):1370-7. PubMed ID: 12196362
[TBL] [Abstract][Full Text] [Related]
42. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
43. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
44. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease.
Roach M; Brophy N; Cox R; Varghese A; Hoppe RT
J Clin Oncol; 1990 Apr; 8(4):623-9. PubMed ID: 2313331
[TBL] [Abstract][Full Text] [Related]
46. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols.
Bodis S; Henry-Amar M; Bosq J; Burgers JM; Mellink WA; Dietrich PY; Dupouy N; Noordijk EM; Raemaekers JM; Thomas J
J Clin Oncol; 1993 Feb; 11(2):225-32. PubMed ID: 8426198
[TBL] [Abstract][Full Text] [Related]
47. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
[TBL] [Abstract][Full Text] [Related]
48. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
[TBL] [Abstract][Full Text] [Related]
49. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma.
Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I
Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949
[TBL] [Abstract][Full Text] [Related]
50. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
51. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
52. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome.
Rapoport AP; Rowe JM; Kouides PA; Duerst RA; Abboud CN; Liesveld JL; Packman CH; Eberly S; Sherman M; Tanner MA
J Clin Oncol; 1993 Dec; 11(12):2351-61. PubMed ID: 8246024
[TBL] [Abstract][Full Text] [Related]
53. Is combined modality therapy necessary for advanced Hodgkin's disease?
Mendenhall NP; Bennett CJ; Lynch JW
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):583-92. PubMed ID: 9231683
[TBL] [Abstract][Full Text] [Related]
54. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
Yahalom J; Gulati SC; Toia M; Maslak P; McCarron EG; O'Brien JP; Portlock CS; Straus DJ; Phillips J; Fuks Z
J Clin Oncol; 1993 Jun; 11(6):1062-70. PubMed ID: 8501492
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
56. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
57. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
Sasse S; Alram M; Müller H; Smardová L; Metzner B; Doehner H; Fischer T; Niederwieser DW; Schmitz N; Schäfer-Eckart K; Raemaekers JM; Schmalz O; Tresckow BV; Engert A; Borchmann P
Leuk Lymphoma; 2016 May; 57(5):1067-73. PubMed ID: 26693800
[TBL] [Abstract][Full Text] [Related]
58. Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience.
Koletsky AJ; Bertino JR; Farber LR; Prosnitz LR; Kapp DS; Fischer D; Portlock CS
J Clin Oncol; 1986 Mar; 4(3):311-7. PubMed ID: 3950674
[TBL] [Abstract][Full Text] [Related]
59. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
Sureda A; Arranz R; Iriondo A; Carreras E; Lahuerta JJ; García-Conde J; Jarque I; Caballero MD; Ferrà C; López A; García-Laraña J; Cabrera R; Carrera D; Ruiz-Romero MD; León A; Rifón J; Díaz-Mediavilla J; Mataix R; Morey M; Moraleda JM; Altés A; López-Guillermo A; de la Serna J; Fernández-Rañada JM; Sierra J; Conde E;
J Clin Oncol; 2001 Mar; 19(5):1395-404. PubMed ID: 11230484
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.
Sureda A; Constans M; Iriondo A; Arranz R; Caballero MD; Vidal MJ; Petit J; López A; Lahuerta JJ; Carreras E; García-Conde J; García-Laraña J; Cabrera R; Jarque I; Carrera D; García-Ruiz JC; Pascual MJ; Rifón J; Moraleda JM; Pérez-Equiza K; Albó C; Díaz-Mediavilla J; Torres A; Torres P; Besalduch J; Marín J; Mateos MV; Fernández-Rañada JM; Sierra J; Conde E;
Ann Oncol; 2005 Apr; 16(4):625-33. PubMed ID: 15737986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
